Related Experiment Video

Updated: Aug 26, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

[Use of beta blockers in cardiovascular diseases and bronchial asthma/COPD]

T Glaab1, T Weiss

  • 1Abteilung für Pneumologie, Medizinische Hochschule Hannover. thomasglaab@web.de

Der Internist
|March 3, 2004
PubMed

Insights

Beta-blockers significantly reduce mortality in heart failure and heart attack patients. Cardioselective beta-blockers may benefit COPD and mild asthma patients, outweighing risks when prescribed cautiously.

Area of Science:

  • Cardiology
  • Pulmonology
  • Pharmacology

Background:

  • Beta-blockers are proven life-saving therapies for myocardial infarction and chronic heart failure, reducing total mortality.
  • However, this essential treatment is frequently withheld from patients with chronic obstructive pulmonary disease (COPD) and asthma due to concerns about respiratory side effects.
  • Patients with COPD, in particular, have a high cardiovascular risk profile and may significantly benefit from beta-blocker therapy.

Purpose of the Study:

  • To evaluate the safety and efficacy of beta-blocker therapy in patients with COPD and asthma.
  • To determine if the mortality benefits of beta-blockers outweigh the potential risks in these patient populations.
  • To provide guidance on the appropriate use of beta-blockers in patients with comorbid respiratory conditions.

Main Methods:

  • Review of extensive randomized clinical trials and recent meta-analyses on beta-blocker use.
  • Analysis of data regarding the tolerability and impact on lung function of cardioselective beta-blockers in COPD/asthma patients.
  • Assessment of the benefit-to-risk ratio for beta-blocker therapy in patients with COPD and mild asthma.

Main Results:

  • Cardioselective beta-blockers are generally well-tolerated in COPD patients, with no significant limitations in lung function observed.
  • Findings suggest that the mortality reduction associated with beta-blocker therapy may outweigh the risks for patients with COPD and potentially mild asthma.
  • Contraindications include acute exacerbations, severe COPD, moderate to severe asthma, and regular use of beta(2)-sympathomimetics.

Conclusions:

  • Beta-blocker therapy, particularly with cardioselective agents, can be beneficial for patients with COPD and mild asthma.
  • Careful individual assessment of the benefit-to-risk ratio is crucial, starting with low doses.
  • Cardioselective beta-blockers with proven mortality benefits should be considered for these high-risk patient groups.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...